title: Tumor suppressor gene co-operativity in compound Patched1 and suppressor of fused heterozygous mutant mice.
abstract: Dysregulation of the Hedgehog signaling pathway is central to the development of certain tumor types, including medulloblastoma and basal cell carcinoma (BCC). Patched1 (Ptch1) and Suppressor of fused (Sufu) are two essential negative regulators of the pathway with tumor suppressor activity. Ptch1(+/-) mice are predisposed to developing medulloblastoma and rhabdomyosarcoma, while Sufu(+/-) mice develop a skin phenotype characterized by basaloid epidermal proliferations. Here, we have studied tumor development in Sufu(+/-)Ptch1(+/-) mice to determine the effect of compound heterozygosity on the onset, incidence, and spectrum of tumors. We found significantly more (2.3-fold) basaloid proliferations in Sufu(+/-)Ptch1(+/-) compared to Sufu(+/-) female, but not male, mice. For medulloblastoma, the cumulative 1-yr incidence was 1.5-fold higher in Sufu(+/-)Ptch1(+/-) compared to Ptch1(+/-) female mice but this strong trend was not statistically significant. Together this suggests a weak genetic interaction of the two tumor suppressor genes. We noted a few rhabdomyosarcomas and pancreatic cysts in the Sufu(+/-)Ptch1(+/-) mice, but the numbers were not significantly different from the single heterozygous mice. Hydrocephalus developed in approximately 20% of the Ptch1(+/-) and Sufu(+/-)Ptch1(+/-) but not in Sufu(+/-) mice. Interestingly, most of the medulloblastomas from the Sufu(+/-)Ptch1(+/-) mice had lost expression of the remaining Ptch1 wild-type allele but not the Sufu wild-type allele. On the contrary, Sufu as well as Gli1 and Gli2 expression was upregulated in the medulloblastomas compared to adult cerebellum in Ptch1(+/-) and Sufu(+/-)Ptch1(+/-) mice. This suggests that Sufu expression may be regulated by Hedgehog pathway activity and could constitute another negative feedback loop in the pathway.
authors.affiliation: Department of Biosciences and Nutrition, Karolinska Institutet, Huddinge, Sweden.
authors.forename: Jessica
authors.initials: J
authors.lastname: Svärd
authors.forename: Björn
authors.initials: B
authors.lastname: Rozell
authors.forename: Rune
authors.initials: R
authors.lastname: Toftgård
authors.forename: Stephan
authors.initials: S
authors.lastname: Teglund
mesh_terms: D000818:Animals; D005260:Female; D016147:Genes, Tumor Suppressor; D007150:Immunohistochemistry; D008297:Male; D008527:Medulloblastoma / Q000235:genetics; D051379:Mice; D018345:Mice, Knockout; D008817:Mice, Mutant Strains; D000072079:Patched Receptors; D000072081:Patched-1 Receptor; D011956:Receptors, Cell Surface / Q000235:genetics*; D012097:Repressor Proteins / Q000235:genetics*; D020133:Reverse Transcriptase Polymerase Chain Reaction
chemical_list: C000606236:PTCH1 protein, human; D000072079:Patched Receptors; D000072081:Patched-1 Receptor; C000606240:Ptch1 protein, mouse; D011956:Receptors, Cell Surface; D012097:Repressor Proteins; C490764:SUFU protein, human
references.citation: Nat Rev Genet. 2006 Nov;7(11):841-50
references.pmid: 17047684
references.citation: Dev Cell. 2006 Feb;10(2):187-97
references.pmid: 16459298
references.citation: J Biol Chem. 2000 Sep 15;275(37):28341-4
references.pmid: 10884376
references.citation: Nat Cell Biol. 1999 Sep;1(5):312-9
references.pmid: 10559945
references.citation: Nat Rev Cancer. 2003 Dec;3(12):903-11
references.pmid: 14737121
references.citation: Cancer Res. 2001 Jan 15;61(2):513-6
references.pmid: 11212243
references.citation: Development. 2005 May;132(10):2425-39
references.pmid: 15843415
references.citation: Nature. 2003 Oct 23;425(6960):851-6
references.pmid: 14520413
references.citation: Cancer Res. 2006 Feb 15;66(4):2081-8
references.pmid: 16489008
references.citation: Oncogene. 2007 Sep 27;26(44):6442-7
references.pmid: 17452975
references.citation: Development. 1999 Oct;126(20):4431-40
references.pmid: 10498679
references.citation: J Pathol. 2006 Jan;208(1):17-25
references.pmid: 16294371
references.citation: PLoS Biol. 2006 Apr;4(4):e86
references.pmid: 16602821
references.citation: Genes Dev. 2001 Dec 1;15(23):3059-87
references.pmid: 11731473
references.citation: Oncogene. 2002 Oct 24;21(49):7580-4
references.pmid: 12386820
references.citation: Nat Med. 1999 Nov;5(11):1285-91
references.pmid: 10545995
references.citation: Nat Genet. 2002 Jul;31(3):306-10
references.pmid: 12068298
references.citation: Neuropathol Appl Neurobiol. 2004 Oct;30(5):532-9
references.pmid: 15488029
references.citation: Nat Cell Biol. 2007 Sep;9(9):1005-9
references.pmid: 17762891
references.citation: Cancer Cell. 2004 Sep;6(3):229-40
references.pmid: 15380514
references.citation: Science. 1997 Aug 22;277(5329):1109-13
references.pmid: 9262482
references.citation: Cell. 1996 Jun 14;85(6):841-51
references.pmid: 8681379
references.citation: Cancer Res. 2000 Apr 15;60(8):2239-46
references.pmid: 10786690
references.citation: Nat Clin Pract Oncol. 2007 May;4(5):295-304
references.pmid: 17464337
references.citation: Science. 2002 Aug 30;297(5586):1559-61
references.pmid: 12202832
references.citation: Cancer Res. 2006 Jul 15;66(14):6964-71
references.pmid: 16849540
references.citation: Genet Med. 2004 Nov-Dec;6(6):530-9
references.pmid: 15545751
references.citation: Oncogene. 2006 Sep 7;25(40):5575-80
references.pmid: 16636673
references.citation: Cancer Res. 2006 Oct 15;66(20):10171-8
references.pmid: 17047082
references.citation: Science. 1996 Jun 14;272(5268):1668-71
references.pmid: 8658145
references.citation: Nat Med. 1998 May;4(5):619-22
references.pmid: 9585239
references.citation: Development. 2005 Oct;132(19):4407-17
references.pmid: 16155214